A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

NCT03398655 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

408

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Platinum Resistant Ovarian Cancer

Interventions

DRUG: VB-111 + Paclitaxel
DRUG: Placebo + Paclitaxel

Sponsor

Vascular Biogenics Ltd. operating as VBL Therapeutics

Collaborators

[object Object]